AUS
NZ
UK
CA
USA
IND
Highlights:
- ADMA Biologics Inc’s Q3 2022 revenue was US$ 41.4 million.
- Trevi Therapeutics Inc. posted total assets of US$ 128.36 million in Q3 2022.
- Voyager Therapeutics achieved a collaboration revenue of US$ 41.086 million in Q3 2022.
Penny stocks can be highly risky to invest in because the performance of the individual companies varies a lot. However, since they are cheaper, investors tend to get lured by them. One must look at market conditions and the company fundamentals before investing in penny stocks. Moreover, the market condition has also been volatile since the start, making it even riskier.
Here, we take a look at three penny stocks and their performances in recent quarters:
ADMA Biologics Inc (NASDAQ:ADMA)
ADMA Biologics is a biopharmaceutical company that manufactures, markets, and develops plasma-derived biologics used to treat infectious diseases.
The company posted a revenue of US$ 41.4 million in the third quarter of 2022, up 99 per cent from the same period in 2021. Its gross profit in the reported quarter was US$ 9.65 million compared to US$ 0.385 million in the year-ago quarter.
The company's net loss in Q3 2022 came down to US$ 14.899 million against a net loss of US$ 17.712 million in Q3 2021.
The ADMA stock surged over 151 per cent YTD.
Trevi Therapeutics Inc. (NASDAQ: TRVI)
Trevi Therapeutics develops and sells/distributes nalbuphine ER to treat serious neurologically mediated conditions. The biopharmaceutical company has a price-to-book (P/B) ratio of 1.017.
The clinical-stage company said its R&D expenses for the third quarter of 2022 was US$ 5.8 million. It was higher than US$ 4.7 million in the corresponding quarter in the previous year. This increase was mainly due to its various startup activities for the scheduled trials.
At the end of the quarter that ended September 30, 2022, Trevi had total assets of US$ 128.36 million compared to US$ 38.47 million at the end of the quarter that ended December 31, 2021. The company reported a net loss of US$ 8.266 million in Q3 2022 compared to US$ 7.255 million in the year-ago quarter. The TRVI stock soared over 148.10 per cent year-to-date.
Source: ©Kalkine Media®; © Canva via Canva.com
Voyager Therapeutics Inc. (NASDAQ: VYGR)
Gene therapy company Voyager Therapeutics develops life-changing treatments for patients with severe neurological diseases.
In the third quarter of fiscal 2022, Voyager posted a collaboration revenue of US$ 41.086 million compared to just US$ 1.482 million in the same quarter in 2021. The company’s net income in Q3 2022 was US$ 17.62 million versus a loss of US$ 25.13 million in the corresponding quarter a year ago.
Notably, the diluted net income per share was US$ 0.45 in the third quarter of this year compared to loss of US$ 0.67 in Q3 2021. The VYGR stock climbed over 96.65 per cent YTD.
Bottom line:
Participants are always wary of losing their money in a volatile stock market. However, if you have a long-term strategy and a diversified portfolio, about it might help you adapt to the frequently changing market conditions. Just do your analysis thoroughly and then take any decisions to stay protected in a bearish market trend.
